中國銀河(06881.HK)擬發行78億元A股可轉債
格隆匯3月21日丨中國銀河(06881.HK)公吿,公司公開發行A股可轉債已獲得中國證券監督管理委員會證監許可[2022]547號文核准。本次發行的A股可轉債簡稱為中銀轉債,本次發行人民幣78億元A股可轉債,每張面值為人民幣100元,共計7,800萬張,780萬手,按面值發行。本次發行的A股可轉債期限為自發行之日起六年,即自2022年3月24日至2028年3月23日。
票面利率分別為第一年0.2%、第二年0.4%、第三年0.6%、第四年1.0%、第五年1.8%及第六年2.0%。在本次發行的A股可轉債期滿後五個交易日內,公司將以本次A股可轉債票面面值的106%(含最後一期利息)的價格贖回全部未轉股的A股可轉債。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.